Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion

- The Singaporean sovereign wealth fund (GIC) becomes a strategic investor by investing USD 1 billion to acquire a minority stake in Biomat USA, a Grifols subsidiary with 300 U.S.-based plasma centers that will remain under Grifols' management.

- This investment supports Grifols' strategy to expand and reinforce its U.S. plasma-center network.

- All funds raised will be allocated to repay debt as part of Grifols' commitment to reduce its leverage levels.

- Grifols has obtained all necessary regulatory approvals to close the transaction.

*Barcelona, November 17, 2021.* - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare leader dedicated for more than 110 years to enhancing the health and well-being of patients worldwide, and GIC, Singapore’s sovereign wealth fund, have obtained all necessary regulatory approvals, including authorization from the Committee on Foreign Investment in the United States (CFIUS), to close their strategic agreement announced in June.

Consequently, GIC will invest approximately USD 1 billion in Biomat USA, a wholly owned Grifols subsidiary, and become a strategic investor in the company by securing a minority stake in Biomat USA via the acquisition of newly issued non-voting preferred shares.

Grifols will continue to control all management and operational aspects of Biomat’s U.S. plasma-center network, which includes 300 centers throughout the United States. Therefore, this agreement includes a long-term contract by which Grifols will continue to receive all obtained plasma for the production of plasma-derived medicines.

As Grifols CFO Alfredo Arroyo shares, “We are very pleased to have obtained all necessary regulatory requirements to close this strategic transaction, which underlines the confidence of a fund as solvent as GIC in our business model. We continue to make progress and all proceeds will be used to repay debt to meet our current commitments.”

The company continues its efforts to quickly and progressively lower its debt ratio to below 3.5x by 2024.
About GIC’s minority stake in Biomat USA

Under the final Grifols-GIC agreement, the Singaporean sovereign wealth fund will invest USD 990 million in Biomat, which operates 300 plasma centers across the United States.

In exchange, GIC will receive ten Class B ordinary Biomat shares and nine Class B ordinary shares of a newly created sub-holding company. These ordinary shares will directly and indirectly represent 23.8% of Biomat's share capital.

Grifols retained Osborne Clarke, S.L.P and Proskauer Rose, L.L.P as legal advisors for the transaction, and Nomura Securities International, Inc. as sole financial advisor. GIC retained Dechert LLP as legal advisor.

Investor contact:
Investor Relations and Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21

Media contacts:

<table>
<thead>
<tr>
<th>Raquel Lumbreras</th>
<th>Grifols Media Press Office</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:Raquel_lumbreras@duomocomunicacion.com">Raquel_lumbreras@duomocomunicacion.com</a></td>
<td><a href="mailto:media@grifols.com">media@grifols.com</a></td>
</tr>
<tr>
<td>Borja Gómez</td>
<td>Tel. +34 571 00 02</td>
</tr>
<tr>
<td><a href="mailto:Borja_gomez@duomocomunicacion.com">Borja_gomez@duomocomunicacion.com</a></td>
<td></td>
</tr>
<tr>
<td>Duomo Comunicación – Grifols Press Office</td>
<td></td>
</tr>
<tr>
<td>Tel. +34 91 311 92 89 - 91 311 92 90</td>
<td></td>
</tr>
<tr>
<td>+34 659 57 21 85 / +34 650 40 22 25</td>
<td></td>
</tr>
</tbody>
</table>

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.
The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer for purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.